XML 52 R11.htm IDEA: XBRL DOCUMENT v3.25.4
Segment Reporting
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company’s chief operating decision makers (the “CODM function”), which are the Company’s Co-Chief Executive Officers, Mr. Duggan and Dr. Zanganeh, and Chief Operating Officer and Chief Financial Officer, Mr. Soni, utilize consolidated net loss that is reported on the consolidated statement of operations and comprehensive loss to make decisions about allocating resources and assessing performance for the entire Company. The CODM function approves of key operating and strategic decisions, including key decisions in clinical development and clinical operating activities, entering into significant contracts, such as revenue contracts and collaboration agreements and approves the Company’s consolidated operating budget. The CODM function views the Company's operations and manages its business on a consolidated basis and as a single reportable operating segment. The CODM function is regularly provided with the following significant segment expenses:

Year Ended December 31,
 202520242023
Oncology clinical trial related costs$266,439 $100,937 $35,224 
Acquired in-process research and development— 15,007 520,915 
Compensation related costs, excluding stock-based compensation75,575 48,295 31,371 
Stock-based compensation732,420 50,981 14,108 
Other expenses (1)
19,990 10,778 8,032 
Total segment expenses
1,094,424 225,998 609,650 
Other income, net14,838 13,369 11,183 
Interest expense— (8,686)(16,461)
Net loss$(1,079,586)$(221,315)$(614,928)

(1) Other expenses include general and administrative expenses excluding compensation and stock-based compensation.

As of December 31, 2025 and 2024, substantially all of our long-lived assets are located in the United States.